These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25884692)

  • 1. Prognostic role of serum p53 antibodies in lung cancer.
    Mattioni M; Soddu S; Prodosmo A; Visca P; Conti S; Alessandrini G; Facciolo F; Strigari L
    BMC Cancer; 2015 Mar; 15():148. PubMed ID: 25884692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The detection of quantitative serum p53 protein in lung cancer.
    Sen E; Gönüllü U; Akar N
    Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
    Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
    Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer.
    Laudanski J; Burzykowski T; Niklinska W; Chyczewski K; Furman M; Niklinski J
    Lung Cancer; 1998 Dec; 22(3):191-200. PubMed ID: 10048472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
    Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
    BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases.
    Neri M; Betta P; Marroni P; Filiberti R; Cafferata M; Mereu C; Ivaldi G; Montanaro F; Puntoni R; Paganuzzi M
    Lung Cancer; 2003 Feb; 39(2):165-72. PubMed ID: 12581569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
    Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
    Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
    Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
    Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma.
    Dalquen P; Sauter G; Torhorst J; Schultheiss E; Jordan P; Lehmann S; Solèr M; Stulz P; Mihatsch MJ; Gudat F
    J Pathol; 1996 Jan; 178(1):53-8. PubMed ID: 8778317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
    Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
    Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The presence of anti-p53 antibodies in sera prior to thoracic surgery in non small cell lung cancer patients: its implications on tumor volume, nodal involvement, and survival.
    Bergqvist M; Brattström D; Lamberg K; Hesselius P; Wernlund J; Larsson A; Wagenius G
    Neoplasia; 2003; 5(4):283-7. PubMed ID: 14511399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis.
    Pelletier MP; Edwardes MD; Michel RP; Halwani F; Morin JE
    Can J Surg; 2001 Jun; 44(3):180-8. PubMed ID: 11407827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis.
    Pappot H; Francis D; Brünner N; Grondahl-Hansen J; Osterlind K
    Clin Cancer Res; 1996 Jan; 2(1):155-60. PubMed ID: 9816102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of circulating anti-p53 antibodies in lung cancer--a review.
    Kumar S; Mohan A; Guleria R
    Eur J Cancer Care (Engl); 2009 May; 18(3):248-54. PubMed ID: 19432918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer.
    Passlick B; Izbicki JR; Häussinger K; Thetter O; Pantel K
    J Thorac Cardiovasc Surg; 1995 Jun; 109(6):1205-11. PubMed ID: 7776684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
    Murray PV; Soussi T; O'Brien ME; Smith IE; Brossault S; Norton A; Ashley S; Tavassoli M
    Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.